U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Omalizumab (marketed as Xolair) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Omalizumab (marketed as Xolair) Information

Xolair is an injectable medicine for patients 12 years of age and older with moderate to severe persistent allergic asthma whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program, using the contact information at the bottom of this page.

Healthcare Professional Information

Other Information